The debate in Italy around the Canabidiol legislation is being served. But will CBD be accessible to all? But will CBD be accessible to all?
Article written by Gda. Rocío Serrano Carrascal
On October 1, 2020, the Minister of Health, Roberto Speranza, issued Decree No. 255, which includes in Table B of drugs the compounds for oral ingestion of canabidiol obtained from cannabis extracts.
Concretamente, en Italia los estupefacientes y las sustancias psicotrópicas se clasifican en cinco tablas llamadas Tablas I, II, III y IV y Tabla de Medicamentos, que a su vez se dividen en las secciones A, B, C, D y E.
The insertion of CBD in this table will recognize its use as a drug to treat diseases; in fact, the Italian Medicine Agency approved its compassionate use in Lenoux-Gastox syndromes and Dravet syndrome.
So cannabis is a drug?
A drug is a substance that induces depression in the central nervous system (CNS): stupor, anesthesia and immobilization. Drugs are usually derived from opium, such as morphine. Drugs are usually derived from opium, such as morphine.
According to the decree, which will come into effect on October 30th, the CBD will be introduced in Table B together with benzodiazepines and barbiturates, both psychoactive drugs with depressive effects of the CNS, the use of which produces dependence.
Is it fair that the CBD is legislated like these drugs?
The CBD is not a psychotropic drug, that is, it does not act on the brain. CBD binds to CB2 receptors that are not found in the brain, but in the rest of the body; furthermore, CBD does not easily pass the blood-brain barrier, a barrier that “selects” substances that can pass to the brain and those that cannot.
On the other hand, scientific studies specify that CBD does not produce dependency, as barbiturates or benzodiazepines do.
We can then say that we are dealing with a special substance. CBD has several effects on the human organism that are supported by scientific studies, but these effects are not comparable to the effects produced by the consumption of narcotics or psychotropic drugs, including the risks derived from their consumption.
What are the consequences of restricting the CBD to prescription-only use?
Today, many people are aware of the advantages of cannabis. The inclusion of CBD in this table may have several consequences, such as:
- Making access to CBD more difficult by restricting the enjoyment of its therapeutic benefits, such as use under anxiety or stress.
- As it is illegal to buy and sell cannabis products or derived products, there will be no sanitary control to ensure the identity or correct condition of the products being purchased.
- Destruction of jobs, those people who until now had formed their business around the “light of cannabis”.
- Cannabis will continue to be sold on the black market, which will increase the underground economy.
- Remaining on the black market will not only lead to unpleasant circumstances for buying and selling, but will also help to increase the negative stereotypes and taboos around this plant.
What do other countries think about the use of the CBD?
In the UK, France, Switzerland, Luxembourg, Ireland, Netherlands, Austria, Spain, Portugal or most US states; CBD is not a psychotropic compound, therefore its use is permitted.
1. White CM. A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential. J Clin Pharmacol. 2019;59(7):923–34.
2. Di Marzo V, Piscitelli F. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics. 2015;12(4):692–8.
3. Carmichael O, Lockhart S. Neurotrophins and. Brain Imaging Behav Neurosci
4. Löscher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012;53 Suppl 8:12–25.
5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Opioids.